We are excited to be making plans for an in-person E-Cigarette Summit US to be held in Washington D.C on May 9, 2022.

For those that were not able to join us for the Virtual Summit – held  May 25-26, the videos can now be viewed on the Agenda page.  We will be announcing the new 2022 program and speakers in due course.

The details on this site currently relate to the 2021 event.

The Summit comes at a time of great change within the U.S. regulatory and tobacco control environments.  The long-awaited PMTA deadline came and went on September 9, 2020 and the FDA is under a Court Order to process applications within 12 months of that date. It remains to be seen how pragmatic or strict  the FDA’s review will be in practice – and thus whether we will see a marketplace with only a handful or, conversely, a wide variety, of authorized ENDS products.  How the FDA’s application of the “appropriate for the protection of public health” standard is interpreted will have far reaching consequences for policy makers, public health and tobacco control.

The fears raised over youth initiation of e-cigarettes has often overshadowed discussion regarding the potential for adult smoking populations. This has turned into an extended and unhelpful conflict, splitting public health into factions and pitting former allies in tobacco control communities against each other. This has increasingly spilled over into the scientific community where we have seen the same data interpreted differently. The challenge this presents for both state and federal regulators should not be underestimated.

All of this occurs in the shadow of Covid-19, which has again placed a spotlight on health inequities. The national smoking rate has fallen to historic lows, but the socioeconomic gap has never been bigger. Wealthier and more-educated Americans are now largely spared the cost of smoking related death and disease. This is a phenomenon  is replicated similarly in other developed countries.  If we are to reach the “Smoke free” and “tobacco end game goals” it will be through a combined effort of tobacco control,  public health and regulatory strategies.

The E-Cigarette Summit has a single aim of facilitating respectful dialogue and thoughtful analysis of the latest research and exploring how the evidence should be interpreted, to deliver the most effective health strategies to reduce smoking related death and disease.  The role that e-cigarettes and tobacco harm reduction could play in ending or extending the smoking epidemic is likely to remain one of the most fiercely fought debates in public health history. We cannot answer every question yet, but we believe that progress is not only possible but imperative.


Prof Thomas Glynn

Stanford University School of Medicine

Prof Thomas J. Glynn, Stanford University School of Medicine


Deborah Arnott

Chief Executive

Action on Smoking and Health (UK)

Dr Michael Pesko

Associate Professor, Dep't of Economics

Andrew Young School of Policy Studies, Georgia State University

Prof Scott Leischow

Professor, College of Health Solutions

Arizona State University

Dr Alex Wodak


Australian Drug Law Reform

Dr. Jasjit S. Ahluwalia

Professor, Behavioural and Social Sciences & Internal Medicine

Brown University, School of Public Health & Alpert School of Medicine

Clive Bates


Counterfactual Consulting Ltd

Ruoyan Sun

Assistant Professor

Dep't of Health Care Organization & Policy, School of Public Health,University of Alabama at Birmingham

Abigail Friedman

Assistant Professor

Dept of Health Policy & Management, Yale School of Public Health

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Ethan Nadelmann


Drug Policy Alliance

Tim Phillips

Managing Director


Kathleen Crosby

Director, Office of Health Communication & Education

FDA Center for Tobacco Products

Stefanie Miller

Managing Director

FiscalNote Markets

Prof Richard Miech

Principal Investigator, Monitoring the Future

Institute for Social Research, University of Michigan

Professor Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Prof Mike Cummings

Professor, Dep't Psychiatry & Behavioural Sciences

Medical University of South Carolina

David Graham

Chief Impact Officer


Jamie Hartmann-Boyce

Senior Research Fellow and Editor, Cochrane Tobacco Addiction Group

Nuffield Department of Primary Care Health Sciences, University of Oxford

Prof Scott Sherman

Professor of Population Health, Medicine and Psychiatry

NYU Grossman School of Medicine

Dr Ray Niaura

Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab

School of Global Public Health, New York University

Dr Cheryl Healton DrPH

Dean and Professor of Public Health Policy and Management

School of Global Public Health, New York University

Prof Kenneth Warner

Professor Emeritus and Dean Emeritus

School of Public Health, University of Michigan

Cliff Douglas, JD

Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy

School of Public Health, University of Michigan

Jaron King

Surveillance Co-ordinator

South Carolina Division of Tobacco Prevention and Control

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Matthew R. Holman

Director, Office of Science (OS),Center for Tobacco Products (CTP)

U.S. Food and Drug Administration

Prof Neal L. Benowitz

Professor of Medicine and Bioengineering & Theapeutic Sciences

University of California, San Franciso

Dr Robin Mermelstein

Professor of Psychology and IHRP Director

University of Illinois, Chicago

Asst. Prof Jennifer Pearson

Assistant Professor in Health Administration and Policy, School of Community Health Sciences

University of Nevada, Reno School of Community Health Sciences

Ben Youdan


Youdan Consulting - New Zealand


The E-Cigarette Summit provides an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics. The format includes high level briefings from global experts followed by panel discussions and audience Q&A.

  • What are the likely impacts of the FDA’s implementation of the PMTA
  • Balancing intended and unintended consequences of regulatory interventions
  • How should the “harm continuum” of reduced risk nicotine products be communicated to achieve public health goals
  • Helping adult smokers utilizing THR vs preventing youth initiation – are these two priorities compatible?
  • Why has THR proved to be so divisive – how can we improve the dialogue
  • Socio-economic health disparities related to smoking is a public health crisis  – Has it received enough attention
  • Flavored tobacco products – the importance of differentiating combustibles on the harm continuum
  • What can different national and international approaches to nicotine caps and flavor bans teach us
  • Is a “smoke free” goal synonymous with the “tobacco end game”
  • What are the current and future research priorities


The E-Cigarette Summit is particularly relevant to:

  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders


  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders